Senna and Skin hyperpigmentation - a phase IV clinical study of FDA data

Summary:

Skin hyperpigmentation is reported as a side effect among people who take Senna (senna), especially for people who are female, 40-49 old, also take Magnevist, and have Dysmenorrhea.

The phase IV clinical study analyzes which people have Skin hyperpigmentation when taking Senna. It is created by eHealthMe based on reports of 37,042 people who have side effects when taking Senna from the FDA, and is updated regularly.

What is Senna?

Senna has active ingredients of senna. It is often used in constipation. eHealthMe is studying from 37,302 Senna users. Check the latest studies of Senna.

What is Skin hyperpigmentation?

Skin hyperpigmentation (disorders affect the colour of your skin) is found to be associated with 646 drugs and 811 conditions by eHealthMe. Check the latest studies of Skin hyperpigmentation.

On Jul, 17, 2026

37,042 people reported to have side effects when taking Senna.
Among them, 31 people (0.08%) have Skin hyperpigmentation.

Could Senna cause Skin hyperpigmentation?

Among these 31 people:

What is the gender of people who have Skin hyperpigmentation when taking Senna? *

female: 76.67 %
male: 23.33 %

What is the age of people who have Skin hyperpigmentation when taking Senna? *

What are other drugs people take besides Senna? *

What are other side effects people have besides Skin hyperpigmentation? *

Stress And Anxiety: 17 people, 54.84%
Oedema Peripheral (superficial swelling): 16 people, 51.61%
Dry Skin: 15 people, 48.39%
Joint Pain: 14 people, 45.16%
Nephrogenic Systemic Fibrosis (involves fibrosis of skin, joints, eyes due to kidney disease): 14 people, 45.16%
Pain: 14 people, 45.16%
Skin Hypertrophy (skin cells enlarges): 14 people, 45.16%
Skin Tightness: 14 people, 45.16%
Excoriation (to tear or wear off the skin of): 13 people, 41.94%
Itching: 13 people, 41.94%

What are the existing conditions these people have? *

Asthma: 4 people, 12.90%
Dysmenorrhea (painful menstruation): 4 people, 12.90%
Acute Lymphocytic Leukaemia Recurrent (cancer in which the bone marrow makes too many lymphocytes-recurrent): 2 people, 6.45%
Pain: 2 people, 6.45%
Ovarian Cancer (cancer of ovary): 2 people, 6.45%
Oligodendroglioma (a type of glioma that are believed to originate from the oligodendrocytes of the brain or from a glial precursor cell): 2 people, 6.45%
Hypoparathyroidism (inadequate secretion of parathyroid hormone resulting in abnormally low levels of calcium in the blood): 2 people, 6.45%
Hypophosphataemia (electrolyte disturbance in which there is an abnormally low level of phosphate in the blood): 1 person, 3.23%
Deficiency Anaemia: 1 person, 3.23%
Dermatitis (inflammation of the skin resulting from direct irritation by an external agent or an allergic reaction to it): 1 person, 3.23%

* Approximation only. Some reports may have incomplete information.

Do you take Senna and have Skin hyperpigmentation?

- Check whether Skin hyperpigmentation is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Senna:

Senna (37,302 reports)

Browse all side effects of Senna:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Skin hyperpigmentation:

Skin hyperpigmentation (646 drugs)

Browse all the conditions that are associated with Skin hyperpigmentation:

Skin hyperpigmentation (811 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on senna (the active ingredients of Senna) and Senna (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.